Armata Pharmaceuticals is a clinical-stage biotechnology company based in Los Angeles, focusing on bacteriophage therapeutics for drug-resistant infections, employing 66 staff. Its lead candidates target Pseudomonas aeruginosa and Staphylococcus aureus infections.
Armata Pharmaceuticals (ARMP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Armata Pharmaceuticals's actual EPS was $0.07, beating the estimate of -$0.36 per share, resulting in a 119.61% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
